Read the full article by MIT about MBI HERE
|
|
|
|
|
|
|
|
|
|
|

Advancing pediatric cancer research: Cure Group 4 meeting updates

On January 29, 2025, MBI researchers joined the latest Cure Group 4 Consortium meeting, connecting experts from the US, Canada, and Germany. The team discussed preparations for two upcoming FDA-approved clinical trials and set new research goals. Dr. Gene Hwang, head of Oncology at Children’s National in Washington, D.C., highlighted the impact of these efforts, […]

Accelerating progress: funding hope for childhood brain cancer

Brain tumors are the leading cause of cancer-related deaths in children, with medulloblastoma relapsing in 30% of cases. Current treatments, developed in the 1980s, often cause severe, lifelong side effects—when survival is even possible. Now, hope is within reach. Three groundbreaking clinical trials are ready to launch, but $3 million is needed to fund and […]

Weathering the storm together

It was a night to celebrate: MBI founder Fernando Goldsztein had the honor of stepping on stage together with MBI partner and medulloblastoma survivor Daniel Scola

MATCHPOINT: Has medulloblastoma met its match?

Duane Mitchell, MD, PhD, co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy at the University of Florida, is leading the MATCHPOINT trial. The treatment uses adoptive cell therapy…

TRIALS APPROVED!

Drs. Duane Mitchell and Elias Sayour of the Cure Group 4 Consortium have received approval from the U.S. Food and Drug Administration (FDA) to test…

A milestone for MBI

Scientists, academics, researchers, businesspeople and media personalities met last Wednesday (10/04) at the Brazilian embassy in Washington…